TUXEDO-3
OFFICIAL TITLE: MULTICENTER, SINGLE-ARM, 3 COHORT, PHASE II TRIAL OF HER3-DXD IN PATIENTS WITH ACTIVE BRAIN METASTASES FROM METASTATIC BREAST CANCER AND NON-SMALL CELL LUNG CANCER, AND IN PATIENTS WITH LEPTOMENINGEAL DISEASE FROM ADVANCED SOLID TUMORS.
Breast cancer and non-small cell lung cancer with brain metastases.
Leptomeningeal disease from advanced solid tumors
II
60
Pending
Spain, Austria
Set-up
CLINICAL TRIAL DETAILS
THE PRIMARY OBJECTIVES ARE TO ASSESS THE EFFICACY OF PATRITUMAB DERUXTECAN BY EVALUATING THE INTRACRANIAL OBJECTIVE RESPONSE RATE IN PATIENTS WITH ACTIVE BRAIN METASTASES FROM METASTATIC BREAST CANCER AND ADVANCED NON-SMALL CELL LUNG CANCER AND TO ANALYZE THE OVERALL SURVIVAL RATES AT 3 MONTHS IN PATIENTS WITH ADVANCED SOLID TUMORS WITH UNTREATED LEPTOMENINGEAL DISEASE. THE STUDY WILL ALSO ASSESS THE ORR, DISEASE CONTROL RATE, TIME TO RESPONSE, DURATION OF RESPONSE, BEST PERCENTAGE CHANGE IN TUMOR BURDEN, OVERALL SURVIVAL, SAFETY, QUALITY OF LIFE, AND NEUROCOGNITIVE AND NEUROLOGICAL FUNCTION.
TUXEDO-3 AT CLINICALTRIALS.GOV
TUMOR TYPE
PHASE
N
SITES
COUNTRY
STATUS
TRIAL RESUME
TUXEDO-3 SITES
SPAIN
Hospital Arnau de Vilanova de Valencia
SPAIN
Hospital Ubiversitari Dexeus
SPAIN
Hospital Quirónsalud Sagrado Corazón
SPAIN
Hospital Ruber Internacional
SPAIN
Hospital Universitari Vall D’Hebron
SPAIN
Hospital Universitario Virgen del Rocío
SPAIN
Medical University of Vienna
AUSTRIA
Medizinische Universität Innsbruck
AUSTRIA
Salzburg Cancer